Search

Your search keyword '"Maji, I"' showing total 38 results

Search Constraints

Start Over You searched for: Author "Maji, I" Remove constraint Author: "Maji, I"
38 results on '"Maji, I"'

Search Results

2. Stochastic Simulation Modelling and Analysis of Out-Patient flow: A Case Study of General Hospital Hadejia, North-western Nigeria

4. Relationship between the Clinical Frailty Scale and short-term mortality in patients ≥ 80 years old acutely admitted to the ICU: a prospective cohort study

5. Relationship between the Clinical Frailty Scale and short-term mortality in patients ≥ 80 years old acutely admitted to the ICU: a prospective cohort study

6. Sepsis at ICU admission does not decrease 30-day survival in very old patients: a post-hoc analysis of the VIP1 multinational cohort study

7. Cumulative Prognostic Score Predicting Mortality in Patients Older Than 80 Years Admitted to the ICU

8. Cumulative Prognostic Score Predicting Mortality in Patients Older Than 80 Years Admitted to the ICU

9. Correction to: Withholding or withdrawing of life-sustaining therapy in older adults (≥ 80 years) admitted to the intensive care unit (Intensive Care Medicine, (2018), 44, 7, (1027-1038), 10.1007/s00134-018-5196-7)

10. Correction to: Withholding or withdrawing of life-sustaining therapy in older adults (≥ 80 years) admitted to the intensive care unit (Intensive Care Medicine, (2018), 44, 7, (1027-1038), 10.1007/s00134-018-5196-7)

11. Withholding or withdrawing of life-sustaining therapy in older adults (≥ 80 years) admitted to the intensive care unit

12. Withholding or withdrawing of life-sustaining therapy in older adults (≥ 80 years) admitted to the intensive care unit

13. The impact of frailty on ICU and 30-day mortality and the level of care in very elderly patients (≥ 80 years)

17. The impact of frailty on ICU and 30-day mortality and the level of care in very elderly patients (≥ 80 years)

18. Sepsis at ICU admission does not decrease 30-day survival in very old patients : a post-hoc analysis of the VIP1 multinational cohort study

20. Contemplating Novel W/O Emulsion Based Gel for Anti-Psoriatic Activity of Tofacitinib in Imiquimod-Induced Balb/C Mice Model.

21. Harnessing the targeting potential of hyaluronic acid for augmented anticancer activity and safety of duvelisib-loaded nanoparticles in hematological malignancies.

22. The Neoteric Paradigm of Biomolecule-Functionalized Albumin-Based Targeted Cancer Therapeutics.

23. Unlocking the potential of flavonoid-based co-crystal and co-amorphous systems.

24. Amphotericin B loaded nanoemulsion: Optimization, characterization and in-vitro activity against L. donovani promastigotes.

25. Dasatinib loaded mucoadhesive lecithin-chitosan hybrid nanoparticles for its augmented oral delivery, in-vitro efficacy and safety.

26. Exploring the current landscape of chitosan-based hybrid nanoplatforms as cancer theragnostic.

27. Acalabrutinib as a novel hope for the treatment of breast and lung cancer: an in-silico proof of concept.

28. Fucoidan-mediated targeted delivery of dasatinib-loaded nanoparticles amplifies apoptosis and endows cytotoxic potential in triple-negative breast cancer.

29. Solid Self Nano-Emulsifying Drug Delivery System of Dasatinib: Optimization, In-vitro , Ex-vivo and In-vivo assessment.

31. Self-nanoemulsifying drug delivery system (SNEDDS) of docetaxel and carvacrol synergizes the anticancer activity and enables safer toxicity profile: optimization, and in-vitro, ex-vivo and in-vivo pharmacokinetic evaluation.

32. Traversing the diverse avenues of exopolysaccharides-based nanocarriers in the management of cancer.

33. Chitosan functionalized PCL nanoparticles bearing tyrosine kinase inhibitor osimertinib mesylate for effective lung cancer therapy.

34. Core-Shell Type Lipidic and Polymeric Nanocapsules: the Transformative Multifaceted Delivery Systems.

35. Expression of stathmin in oral squamous cell carcinoma and its correlation with tumour proliferation.

36. Budding Multi-matrix Technology-a Retrospective Approach, Deep Insights, and Future Perspectives.

37. Solid self emulsifying drug delivery system: Superior mode for oral delivery of hydrophobic cargos.

Catalog

Books, media, physical & digital resources